Eribulin Improves Survival in Advanced Sarcoma


Treating advanced sarcoma with the chemotherapy agent eribulin improves overall survival compared with treatment with standard therapy with dacarbazine.

Treating advanced sarcoma with the chemotherapy agent eribulin improves overall survival compared with treatment with standard therapy with dacarbazine, according to the results of a randomized, open-label, multicenter phase III trial (abstract LBA10502) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2, in Chicago.

“This is the first phase III trial investigating patients with soft-tissue sarcoma to demonstrate an overall survival benefit compared with an active agent,” said lead author Patrick Schöffski, MD, MPH, head of the department of general medical oncology at University Hospitals Leuven in Leuven, Belgium.

Soft-tissue sarcoma is a heterogeneous family of rare diseases, and liposarcoma and leiomyosarcoma are among the more common subtypes. Patients with advanced, metastatic soft-tissue sarcoma have poor outcomes with limited treatment options.

Eribulin, a microtubule dynamics inhibitor, is a synthetic analog of halichondrin B, originating from a marine sponge product. It is primarily a cytotoxic compound that, based on preclinical findings, kills cancer cells via antimitotic effects, Schöffski said.

In preclinical models, eribulin also affects tumor cells via vascular remodeling, reversal of epithelial-mesenchymal transition, suppression of migration, and invasion. The drug is approved in 59 countries as monotherapy in multiple lines for patients with advanced/metastatic breast cancer.

“The efficacy of available drugs for initial therapy of sarcomas is very unsatisfactory, and patients whose disease progresses despite two or more lines of treatment have a very poor prognosis,” Schöffski said. Typically, survival is 1 year or less for the estimated 12,000 people who will be diagnosed this year in the United States with soft-tissue sarcoma.

In the study, 452 sarcoma patients, about three-quarters of them under age 65 years, were randomly assigned to receive either eribulin 1.4 mg/m2 intravenously on days 1 and 8 (228 patients) or dacarbazine 850–1,200 mg/m2 intravenously on day 1 (224 patients) every 21 days until disease progression. All patients had received at least two standard systemic treatment regimens, including an anthracycline.

The trial’s primary endpoint, overall survival, was met. “Patients treated with eribulin experienced a statistically significant improvement in median overall survival as compared with dacarbazine (13.5 months vs 11.5 months; hazard ratio = 0.768; P = .0169),” Schöffski said. Median progression-free survival was 2.6 months in both arms.

Adverse events were in line with the known safety profiles, he said. The most common frequent treatment-related adverse events in the eribulin arm were neutropenia, fatigue, nausea, alopecia, and constipation; 8% of patients stopped treatment due to side effects.

Low platelet counts were more common in the dacarbazine group compared with the eribulin group. Grade 3 and 4 treatment-related side effects occurred more frequently with eribulin than dacarbazine.

“For a disease where such few treatment options exist, a 2-month improvement in survival is significant. The more treatments our patients have access to, the better their chances of improving life expectancy,” Schöffski said.

Gary K. Schwartz, MD, professor of medicine at Columbia University Medical Center, commented: “This is a giant step forward in sarcoma. There has never been a positive study for survival in sarcoma.” The side effects are manageable, he added, and must be balanced against the drug’s benefits.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Related Content